Dai­ichi Sankyo punts $650M col­lab­o­ra­tion pact as Charleston Labs preps a come­back at­tempt on spurned pain drug

What­ev­er rea­son the FDA had in re­ject­ing an ap­pli­ca­tion from Dai­ichi Sankyo and Charleston Lab­o­ra­to­ries for a new pain drug last Feb­ru­ary was ev­i­dent­ly dis­turb­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER